🇺🇸 FDA
Pipeline program

tauroursodeoxycholic acid (TUDCA)

PKUFH-MASLD-MILKHI-2026-01

Phase 2 small_molecule active

Quick answer

tauroursodeoxycholic acid (TUDCA) for Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development is a Phase 2 program (small_molecule) at First Tracks Biotherapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
First Tracks Biotherapeutics
Indication
Metabolic Dysfunction-Associated Steatotic Liver Disease Infant Development
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials